G protein-coupled receptors (GPCRs) are excellent drug targets exploited by majority of the Food and Drug Administration-approved medications, but when modulated, are often accompanied by significant adverse effects. Targeting of other elements in GPCR pathways for improved safety and efficacy is thus an unmet need. The strength of GPCR signaling is tightly regulated by regulators of G protein signaling (RGS) proteins, making them attractive drug targets. We focused on a prominent RGS complex in the brain consisting of RGS7 and its binding partners Gβ5 and R7BP. These complexes play critical roles in regulating multiple GPCRs and essential physiological processes, yet no small molecule modulators are currently available to modify its function. In this study, we report a novel high-throughput approach to screen for small molecule modulators of the intramolecular transitions in the RGS7/Gβ5/R7BP complex known to be involved in its allosteric regulation. We developed a time-resolved fluorescence energy transfer-based in vitro assay that utilizes full-length recombinant proteins and shows consistency, excellent assay statistics, and high level of sensitivity. We demonstrated the potential of this approach by screening two compound libraries (LOPAC 1280 and MicroSource Spectrum). This study confirms the feasibility of the chosen strategy for identifying small molecule modulators of RGS7/Gβ5/R7BP complex for impacting signaling downstream of the GPCRs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906730 | PMC |
| http://dx.doi.org/10.1089/adt.2017.839 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of Potential Modulators of the RGS7/Gβ5/R7BP Complex.
SLAS Discov
October 2021
Department of Neuroscience, The Scripps Research Institute, Jupiter, FL, USA.
Regulators of G protein signaling (RGS) proteins serve as critical regulatory nodes to limit the lifetime and extent of signaling via G protein-coupled receptors (GPCRs). Previously, approaches to pharmacologically inhibit RGS activity have mostly focused on the inhibition of GTPase activity by interrupting the interaction of RGS proteins with the G proteins they regulate. However, several RGS proteins are also regulated by association with binding partners.
View Article and Find Full Text PDFDevelopment of R7BP inhibitors through cross-linking coupled mass spectrometry and integrated modeling.
Commun Biol
April 2020
1Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bldg. 10/Rm 8C-101, Bethesda, MD 20892 USA.
Protein-protein interaction (PPI) networks are known to be valuable targets for therapeutic intervention; yet the development of PPI modulators as next-generation drugs to target specific vertices, edges, and hubs has been impeded by the lack of structural information of many of the proteins and complexes involved. Building on recent advancements in cross-linking mass spectrometry (XL-MS), we describe an effective approach to obtain relevant structural data on R7BP, a master regulator of itch sensation, and its interfaces with other proteins in its network. This approach integrates XL-MS with a variety of modeling techniques to successfully develop antibody inhibitors of the R7BP and RGS7/Gβ5 duplex interaction.
View Article and Find Full Text PDFStructural organization of a major neuronal G protein regulator, the RGS7-Gβ5-R7BP complex.
Elife
December 2018
Department of Neuroscience, The Scripps Research Institute, Jupiter, United States.
Signaling by the G-protein-coupled receptors (GPCRs) plays fundamental role in a vast number of essential physiological functions. Precise control of GPCR signaling requires action of regulators of G protein signaling (RGS) proteins that deactivate heterotrimeric G proteins. RGS proteins are elaborately regulated and comprise multiple domains and subunits, yet structural organization of these assemblies is poorly understood.
View Article and Find Full Text PDFInhibitory Signaling to Ion Channels in Hippocampal Neurons Is Differentially Regulated by Alternative Macromolecular Complexes of RGS7.
J Neurosci
November 2018
Department of Neuroscience, The Scripps Research Institute, Jupiter, Florida 33458,
The neuromodulatory effects of GABA on pyramidal neurons are mediated by GABA receptors (GABARs) that signal via a conserved G-protein-coupled pathway. Two prominent effectors regulated by GABARs include G-protein inwardly rectifying K (GIRK) and P/Q/N type voltage-gated Ca (Ca2) ion channels that control excitability and synaptic output of these neurons, respectively. Regulator of G-protein signaling 7 (RGS7) has been shown to control GABA effects, yet the specificity of its impacts on effector channels and underlying molecular mechanisms is poorly understood.
View Article and Find Full Text PDFA High-Throughput Time-Resolved Fluorescence Energy Transfer Assay to Screen for Modulators of RGS7/Gβ5/R7BP Complex.
Assay Drug Dev Technol
April 2018
1 Department of Neuroscience, The Scripps Research Institute, Jupiter, Florida.
G protein-coupled receptors (GPCRs) are excellent drug targets exploited by majority of the Food and Drug Administration-approved medications, but when modulated, are often accompanied by significant adverse effects. Targeting of other elements in GPCR pathways for improved safety and efficacy is thus an unmet need. The strength of GPCR signaling is tightly regulated by regulators of G protein signaling (RGS) proteins, making them attractive drug targets.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!